Press Kits

The company accelerated its growth in the third quarter of 2024. All three business sectors achieved organic increases in sales and earnings.

Thanks to the good business performance of Healthcare and Electronics, Group sales in the second quarter of 2024 increased by 1.7% organically.

The positive development of Healthcare and Electronics largely compensated for the decline in Life Science.

Merck KGaA, Darmstadt, Germany held its 29th Annual General Meeting virtually today. All of the resolutions on the agenda were approved, including the proposed dividend of € 2.20 per share.

The Group reported financial results for 2023 in line with its guidance published in August despite a challenging market environment, thus demonstrating the robustness of its business model.

The strong organic development of the Healthcare business sector partly compensated for the decline in sales and earnings in Life Science and Electronics.

In the second quarter of 2023, the Group leveraged its diversified portfolio to navigate a challenging market environment.

Merck KGaA, Darmstadt, Germany generated net sales of € 5.3 billion in the first quarter of 2023. This corresponds to an increase of 1.8% over the year-earlier quarter (organically 0.8%).

In fiscal 2022, the Group delivered solid growth in net sales and EBITDA pre.

2022/11/15 - Every two years, the Access to Medicine Foundation, an independent non-profit organization founded in 2005, benchmarks 20 of the world’s largest pharmaceutical companies based on their efforts to advance global access to medicines.

Group Confirms Guidance for 2022 and Delivers Strong Organic Growth in Q3

We continued our growth trajectory in the second quarter of 2022 despite a challenging environment. Group net sales rise by 14.3% to € 5.6 billion.

How we are contributing to the global Covid-19 response.